An observational study in Mitral Valve Disease, sponsored by Medtronic Cardiac Surgery. Completed at 12 sites in 3 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-02-11.
Sponsored by Medtronic Cardiac Surgery (part of Medtronic) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this registry is to gather data on the clinical outcomes of Medtronic mitral repair products (Profile 3D™ and CG Future® annuloplasty systems) in the approved intended use up to 12 months from the day of procedure
There is limited local evidence on mitral repair products in South Asia and a prospective post market registry will provide real world data on clinical outcomes.
Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings will be considered for study participation.
PRESERVE-Mitral Registry is a prospective non-randomized, non-interventional, post-market registry
The objective of this registry is to gather data on the clinical outcomes of Medtronic mitral repair products (Profile 3D™ and CG Future® annuloplasty systems) in the approved intended use up to 12 months from the day of procedure
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trail was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Heath Service Act or 42 CRF 11.24 and 11.44.)
Medtronic Cardiac Surgery is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
as per instructions-for-use (IFU):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings
Improvement in Mitral Regurgitation (MR) Grade at 12-months Post Procedure
This is determined by assessing the level of mitral valve regurgitation using echo, in subjects at 12-months post-procedure compared to the level at baseline. The levels of regurgitation, level 0-4, correspond to the American Society of Echocardiography (ASE) guidelines ranging from no MR, Mild MR, Moderate MR, Moderate- to-Severe MR and Severe MR. A percentage number is calculated to reflect how many participants had an MR improvement.
Time frame: 12 months
All Cause Mortality
All deaths occurring from any cause 12-months post procedure
Time frame: 12 months
Percentage of Participants With Improvement in MR Grade at Discharge and First Follow-up (3-6 Months)
This was determined by assessing the level of mitral valve regurgitation using hemodynamic performance, in subjects at discharge and 3-6 months post-procedure compared to the level at baseline. The levels of regurgitation, level 0-4, correspond to the ASE guidelines ranging from no MR, Mild MR, Moderate MR, Moderate-to-Severe MR and Severe MR
Time frame: At discharge from hospital (up to 7 days) and at first follow-up (3-6month)
Improvement in NYHA Functional Class at Discharge, First Follow-up (3-6 Months) and Second Follow-up (12-months) Compared to Baseline.
The percentage of subjects with an improved New York Heart Association NYHA functional class using a two-sided 95% exact binomial confidence internal measured at discharge, 3-6 months, and 12-months post-procedure and compared to baseline.
Time frame: At discharge from hospital (up to 7 days), at first follow-up (3-6months), and at the second follow-up (12 months)
Hospitalization for Heart Failure at 6 Months and at 12 Months Post Procedure
Subjects who have a non-elective hospital admission for signs and symptoms related to heart failure that results in a one night stay (i.e., where the admission date and the discharge date differ by at least one calendar day)
Time frame: 6 months and 12 months post procedure
Mitral Valve Re-intervention at Discharge, 6 Months and at 12 Months Post Procedure
Subject leaving the operating theater with an implanted Profile 3DTM or CG Future® annuloplasty system and later undergo any surgical or percutaneous interventional catheter procedure that repairs, otherwise alters or adjusts, or replaces the previously implanted annuloplasty system is considered a reoperation
Time frame: At discharge from hospital (up to 7 days), at first follow-up (3-6months), and at the second follow-up (12 months)
Stroke at 6 Months and at 12 Months Post Procedure
Subjects had an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction, where the neurological dysfunction lasts for greater than 24-hours
Time frame: 6 months and 12 months post procedure
New Onset of Atrial Fibrillation, as Evaluated Through Follow up ECG at Discharge, First Follow up (3-6months) and at Second Follow up (12 Months)
New onset of AF is defined as when the subject did not present with prior history of AF at baseline nor was AF detected at baseline visit, but AF did manifest post procedure and was either diagnosed during the study visits (discharge, 3-6 months or 12 months visit) or was otherwise diagnosed during the duration of subject participation in the study. The incidence of new onset AF will be evaluated at discharge, first follow up (3-6 months) and at second follow up (12 months). This endpoint is analyzed for the Successfully Implanted (IMP) cohort and provided as a Kaplan-Meier analysis.
Time frame: At discharge from hospital, (up to 7 days), at first follow-up (3-6month), and at the second follow-up (12 months)
Number of Attempts Required for Procedural Success
Number of surgical attempts required for procedural implant success
Time frame: Procedure (defined as the date of the first attempted procedure through subject leaving the operating theater with an implanted Profile 3D or CG Future annuloplasty system)
Total Bypass Time During the Implant Procedure
Total time a subject is on bypass time as a measure of procedural complexity
Time frame: During the procedure as measured by standard operating procedures at the sites
| Milestone | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Started | 200 |
| Completed | 180 |
| Not completed | 20 |
This is determined by assessing the level of mitral valve regurgitation using echo, in subjects at 12-months post-procedure compared to the level at baseline. The levels of regurgitation, level 0-4, correspond to the American Society of Echocardiography (ASE) guidelines ranging from no MR, Mild MR, Moderate MR, Moderate- to-Severe MR and Severe MR. A percentage number is calculated to reflect how many participants had an MR improvement.
| percentage of participants | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Improvement in Mitral Regurgitation (MR) Grade at 12-months Post Procedure | 97.8 (93.8 to 99.6) |
All deaths occurring from any cause 12-months post procedure
| participants | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| All Cause Mortality | 6 |
This was determined by assessing the level of mitral valve regurgitation using hemodynamic performance, in subjects at discharge and 3-6 months post-procedure compared to the level at baseline. The levels of regurgitation, level 0-4, correspond to the ASE guidelines ranging from no MR, Mild MR, Moderate MR, Moderate-to-Severe MR and Severe MR
| percentage of patients with improved MR | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Discharge | 100 (98.0 to 100) |
| 3-6 month | 97.5 (93.8 to 99.3) |
The percentage of subjects with an improved New York Heart Association NYHA functional class using a two-sided 95% exact binomial confidence internal measured at discharge, 3-6 months, and 12-months post-procedure and compared to baseline.
| percentage of participants | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Discharge | 73.4 (66.0 to 79.9) |
| 3-6 Months | 84.5 (77.8 to 89.8) |
| 12 Months | 83.8 (76.7 to 89.5) |
Subjects who have a non-elective hospital admission for signs and symptoms related to heart failure that results in a one night stay (i.e., where the admission date and the discharge date differ by at least one calendar day)
| Participants | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| 6 Months | 4 |
| 12 Months | 1 |
Subject leaving the operating theater with an implanted Profile 3DTM or CG Future® annuloplasty system and later undergo any surgical or percutaneous interventional catheter procedure that repairs, otherwise alters or adjusts, or replaces the previously implanted annuloplasty system is considered a reoperation
| Participants | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Discharge | 0 |
| Discharge through 6 months | 0 |
| 12 months | 0 |
Subjects had an acute episode of focal or global neurological dysfunction caused by brain, spinal cord, or retinal vascular injury as a result of hemorrhage or infarction, where the neurological dysfunction lasts for greater than 24-hours
| Participants | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| 6 month | 2 |
| 12 month | 0 |
New onset of AF is defined as when the subject did not present with prior history of AF at baseline nor was AF detected at baseline visit, but AF did manifest post procedure and was either diagnosed during the study visits (discharge, 3-6 months or 12 months visit) or was otherwise diagnosed during the duration of subject participation in the study. The incidence of new onset AF will be evaluated at discharge, first follow up (3-6 months) and at second follow up (12 months). This endpoint is analyzed for the Successfully Implanted (IMP) cohort and provided as a Kaplan-Meier analysis.
| percentage of participants | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Discharge | 3.6 (1.6 to 7.8) |
| 3-6 Months | 4.8 (2.4 to 9.6) |
| 12 months | 4.8 (2.1 to 10.8) |
Number of surgical attempts required for procedural implant success
| Participants | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| One Attempt | 177 |
| Two Attempts | 3 |
Total time a subject is on bypass time as a measure of procedural complexity
| Minutes | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Total Bypass Time During the Implant Procedure | 125.1 ± 47.0 |
Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System | 6/180 (3.3%) | 24/180 (13.3%) | 0/180 (0%) |
| Event | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Cardiac Failure CongestiveCardiac disorders | 3/180 |
| Cardiac FailureCardiac disorders | 2/180 |
| DeathGeneral disorders | 2/180 |
| Cerebrovascular AccidentNervous system disorders | 2/180 |
| Pleural EffusionRespiratory, thoracic and mediastinal disorders | 2/180 |
| ArrhythmiaCardiac disorders | 1/180 |
| Atrial FibrillationCardiac disorders | 1/180 |
| Atrial FlutterCardiac disorders | 1/180 |
| Cardiac ArrestCardiac disorders | 1/180 |
| Cardiopulmonary FailureCardiac disorders | 1/180 |
200 total subjects enrolled, 184 had an attempted; and, 180 were successfully implanted and followed. Data reported is for the Successfully Implanted (IMP) cohort n=180.
| Age, Continuous(years) | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Mean | 50.4 ± 15.0 |
| Sex: Female, Male(Participants) | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Female | 65 |
| Male | 115 |
| Race and Ethnicity Not Collected(Participants) | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|
| Region of Enrollment(participants) | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Bangladesh | 23 |
| Nepal | 13 |
| India | 144 |
| Weight(kg) | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Mean | 61.4 ± 12.2 |
| Height(cm) | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Mean | 161.4 ± 9.5 |
| NYHA Classification(Participants) | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| No Heart Failure | 0 |
| Class I | 6 |
| Class II | 91 |
| Class III | 66 |
| Class IV | 9 |
| Cardiac Rhythm(Participants) | Mitral Valve Repair With Profile 3D™ or CG Future® Annuloplasty System |
|---|---|
| Atrial Fibrillation | 10 |
| Atrial Flutter | 2 |
| Normal Sinus Rhythm | 154 |
| Other | 12 |
4 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Apr 2017 to primary completion in Feb 2021, 46 months.
Results were first posted in Feb 2025, 4 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.